PharmaShots | Incisive News in 3 Shots

Subscribe Now

Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives EC's Marketing Authorization as Eight-Week Regimen for Treatment-Naïve Chroni...

March 9, 2020

AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genot

AbbVie's Mavyret (glecaprevir/pibrentasvir) Receives FDA's Approval for its Expanded Indication in Treatment-Naïve Patients with C...

September 27, 2019

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis

AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepati...

August 2, 2019

Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Gilead Reports Results of Selonsertib in P-III STELLAR-4 study for Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis...

February 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us